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OL-048 Dynamic changes of CTLs, NK cells, and
NKT cells in patients with acute hepatitis B
infection
J. Li1 *, Y.P. Han1, K. Jin1, Y.F. Wan1. 1Department of
Infectious Diseases, China
Background: To explore the effects of speciﬁc CTLs, NK and
NKT cells on viral clearance and liver injury in patients with
self-limited AHB.
Methods: Dynamic proﬁles on the frequency of certain
MHC-Pentamer speciﬁc CTLs and lymphocyte subsets in AHB
patients were analyzed and their relationships to changes in
liver function, HBVM, and HBV DNA levels were examined.
ELISPOT was conducted to detect INF-g secretion of speciﬁc
CTLs.
Results: Frequencies of HBV-speciﬁc CTLs in AHB patients
were higher than in CHB patients. HBeAg and HBV DNA
disappeared earlier in AHB patients with a high frequency
of HBV-speciﬁc CTLs. INF-g spots were signiﬁcantly greater
in AHB patients. CD3+CD8+ cells in AHB patients was more
than that in healthy control and reached peak levels at
the second week after admission. NK and NKT cells were
signiﬁcantly lower in AHB patients and were negatively
correlated with the frequency of HBcAg-speciﬁc CTLs.
Conclusions: HBV-speciﬁc CTLs play an important role in
viral clearance and the self-limited process of the disease.
NK and NKT cells are likely involved in the early, non-speciﬁc
immune response to clear the virus that exists in the liver.
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PL-007 Vaccine security: building agile vaccine
capabilities in the Paciﬁc Rim
M. Callahan1,2 *. 1Academic Medicine: Director,
Mass-Casualty Infection Countermeasures, CIMIT,
Division of Infectious Diseases Massachusetts General
Hospital/Harvard Medical School, Boston, Massachusetts,
USA, 2United States Government: Program Director,
Defense Advanced Research Project Agency (DARPA)
Accelerated Manufacture of Pharmaceuticals; Rapid
Vaccine Assessment, 7-Day Biodefense Small Molecule
Discovery; Prophecy: Predicting Pathogen Evolution, USA
In recent decades emerging infectious diseases and
expanding global travel have increased the risk of natural
and human-promulgated infections. The escalating risk
affects all nations and economies. One shared priority for
the global health community is the development of new
capabilities to meet the demand for abundant, inexpensive,
safe and effective vaccines for all nations. In the last
six years there are four examples where conventional
vaccine manufacturing using egg-based or mammalian cell-
produced whole virus inactivated vaccine systems failed
to meet the needs of Governments that were responding
to emerging health threats. Several countries in Africa
and Asia have lamented that pathogens procured under
international collaborations have been transitioned into
valuable vaccines for resource-rich nations without the
donor nation beneﬁting from access or recompense. One
response to these developments is a growing reluctance
of nations to openly share viruses or convalescent serum.
New strategies are therefore needed to ensure vaccine
security for all nations. At this time numerous novel protein
expression and subunit vaccine manufacturing technologies
are under development in Asia, Europe and North America.
A subset of these technologies have attributes which are
proven to reduce the cost and increase the availability of
safe and effective vaccines. This presentation will review
recent commercial and government accomplishments in the
development of vaccine manufacturing platforms developed
in both the East and West. The merits of each platform
in meeting WHO, EMEA and FDA regulatory approval, in
addressing the urgent timelines required for pandemic
response, and the ability to meet public health needs of
participating nations will be presented. The presentation
will focus in particular on proven subunit vaccine expression
technologies which forgo the proven “recombine-grow-kill-
and-ﬁll” strategies of cell and egg based systems, and
technologies which predict vaccine safety and efﬁcacy prior
to clinical trials.
OL-049 Evaluation on external quality control for
diagnosis of Anaplasmosis in China
L.J. Zhang1 *, P. Wang2, X. Jiang3, Z.Y. Qian3, G.Y. Liu4,
L. Lei5, X.S. Liu5, X. Lei6, X.W. Nan6, J.Y. Wu7, Y.J. Yue8,
Z. Zhang8, W.J. Li8, H. Deng9, Y.D. Xia9, H.L. Yu1,
S.W. Wang1. 1National Institute of Communicable Disease
Control and Prevention, China CDC, Beijing 102206,
2Gansu Center for Disease Control and Prevention, 3Hebei
Center for Disease Control and Prevention, 4Jilin Center
for Disease Control and Prevention, 5Liaoning Center for
Disease Control and Prevention, 6Inner Mongolia Center
for Disease Control and Prevention, 7Qinghai Center for
Disease Control and Prevention, 8Shanxi Center for Disease
Control and Prevention, 9Xinjiang Center for Disease
Control and Prevention, China
Objective: To evaluate the performs of the second stage
external quality assessment (EQA) relevant to laboratory
diagnoses of Anaplasmosis in 10 Provincial/City CDCs
laboratories in China.
Methods: The micro-indirect immunoﬂuoresce assay (mIFA)
proposed by WHO Rickettsial Diseases Collaborating Center
was assessed as a standard serological diagnoses technique.
The performances of two nested PCR assays, one testing
for most members of family Rickettsia by amplifying groEL
gene and the other targeting members of family Anaplasm
by amplifying 16SrRNA gene, were evaluated. Participants
received a package containing primers and 5 reference
templates (P1, P2, P3, P4, P5) for PCR tests, and S1 and
S2 reference sera for serological assays. Each laboratory
was asked to perform these procedures by using their
own laboratory condition including equipments and some
reagents except the provided reference materials.
Results: 7 laboratories from 10 participants units returned
their results for testing S1 and S2 references, and among
these 7 Labs, 5 (71.4%) were eligible according to
the assessment criteria. 8 participated laboratories gave
their PCR results and there are signiﬁcant differences
in speciﬁcity and sensitivity of PCR performance among
laboratories, with 62.5% (5/8) of laboratories providing
acceptable results for P1 and P2 PCR references and
50% (5/10) of laboratories deﬁning eligible results for P4, P5,
P6 references. For repeatability evaluation, all laboratories
reported acceptable results.
Conclusion: Each participated laboratory had systematic
error in their performances. Revising these errors should be
performed and internal quality control for these techniques
should be conducted regularly in future surveillance works.
Supported by the national basic research project-
973 plan (2010CB530206), and special project of
key communicable viral hepatitis-research on infectious
diseases surveillance platform of national Sci-Tech key
S32 Abstracts, 5th DICID
project (2009ZX10004 203) and on pathogen laboratory
network surveillance technique (2008ZX10004 008).
OL-050 The condition of mycoplasma infection in
patients with systemic lupus erythematosus
C.W. Wang1 *, X.R. Wang2, H.Y. Ma3. 1Department of
Infectious Diseases, General Hospital of Air Force, People’s
Liberation Army, 2Department of Medical Matters, General
Hospital of Air Force, People’s Liberation Army, 3Clinical
Laboratory Center, General Hospital of Air Force, People’s
Liberation Army, China
Background: To comprehend the relationship between the
mycoplasma infection and systemic lupus erythematosus.
Methods: Mycoplasma hominis, Ureaplasma urealyticum,
and Mycoplasma fermentans were studied by nested
polymerase chain reaction in eyelid, threat, urethra and
blood of 80 patients with systemic lupus erythematosus.
Result: 65.0% of patients with systemic lupus erythematosus
showed the mycoplasma infection at one or more positions
(c2 = 17.33, P< 0.01), in which 12.5% of patients with that
showed the mycoplasma infection at two positions and
6.2% of patients showed the mycoplasma infection at three
positions. 22.4% of patients showed the mycoplasma hominis
infection in the threat (c2 = 3.89, P< 0.05), and 28.2% of
patients showed the Ureaplasma urealyticum infection in
the urethra (c2 = 5.20, P< 0.05).
Conclusion: There were mycoplasmas infected in several
positions of patients with systemic lupus erythematosus.
The risk of contracting systemic lupus erythematosus for
the subject infected with mycoplasma was 16 times for the
control.
OL-051 Factors relevant to prognosis of 166 patients
with varicella
J. Liu1 *, Y. Yan1, J. Zhang2, X.-J. Li1, Z.-D. Deng1.
1Department of Infectious Diseases, The Third Afﬁliated
Hospital of Sun Yat-sen University, 2Cardiothoracic Surgery
Department, The Third Afﬁliated Hospital of Sun Yat-sen
University, China
Objective: To analyze factors correlative with prognosis of
patients with varicella.
Methods: Data of 166 patients with varicella treated in
The Third Afﬁliated Hospital of Sun Yat-sen University were
collected. All the patients were observed for one week.
Correlative analysis of prognosis (recovery, improvement,
no change, death) of patients with varicella and 16
variables were done. These variables included sex, age,
patient sources, seizures season, disease course, history
of contacting with varicella patients, underlying disease,
hormone usage, fever, fever course, clinical symptoms
except chickenpox (sore throat, cough, abdominal pain
or diarrhea, etc.), complications, bacterial infections,
antibiotics usage, Aciclovir usage and ribavirin usage. All
the data was carried out with software SPSS 13.0. Chi
square test was used to compare observed rates, while
Logistic regression methods was used to analyze correlation
between prognosis and observed factors.
Results: Among 166 patients with varicella, 110 cases
(66.3%) recovered completely, 41 cases (24.7%) were
improved, pathogenetic condition of 9 cases (5.4%) had
not changed, 6 (3.6%) were dead before discharge
from hospital. Single factor analysis demonstrated that
disease course, underlying disease, hormone usage,
fever, clinical symptoms except chickenpox and Aciclovir
usage were correlative factors to prognosis of patients
with varicella (c2 = 7.869 25.934, P = 0.000 0.049). The
multivariate Logistic regression analysis suggested that
only disease course (OR = 12.284, P = 0.000), hormone usage
(OR = 5.396, P= 0.020) and Aciclovir usage (OR = 8.486,
P = 0.004) were correlative factors to prognosis. Prognosis
of these patients with disease course above 10 days,
hormone usage and without Aciclovir were worse than that
of others.
Conclusions: Disease course, hormone usage and Aciclovir
usage were correlative factors to prognosis of patients
with varicella. These results would contribute to better
treatment to patients with varicella.
OL-052 Using of nanosilver as a disinfectant in-vitro and
onto hospital surfaces and duration of effect
Z. Aminzadeh1,2 *, J. Mirzaei3, H. Ahari4, M. Tavassoli4,
M. Besharat1, J. Rahmannia4. 1Shaheed Beheshti Medical
University, Tehran, Iran, 2University of Queensland, Centre
for Clinical Research (UQCCR), Royal Brisbane Hospital,
Australia, 3Birjand, Iran, 4Tehran, Iran
Background: Nanosilver has been showed superior
antimicrobial activity towards various microorganisms. The
aim of this study was to determine in-vitro activity of
Nanosilver as a disinfectant and the effect of Nanosilver on
environmental bacterial and fungal colonization onto the
hospital surfaces.
Methods: At ﬁrst, sampling, culture and sensitivity
pattern of some surfaces have been done. Next, in-vitro
antimicrobial activity of antiseptics against microorganisms
was assessed by using disinfectants included Nanosilver,
Deconex 50 AF and Descocid. Finally, assessment of
disinfectant activity on environmental bacterial & fungal
colonisation and the duration of effect were performed in
three rooms of the infectious diseases ward.
Results: In-vitro study showed that S. aureus and coagulase
negative Staphylococcus were eradicated after 5 minutes
contact with each of diainfectants. All of used disinfectants
could eradicate Pseudomonas after 5 minutes but Nanosilver
5ppm. Bacillus was eradicated by Deconex 2% within
30 minutes and by Descocid 2% and 4% within 5 minutes
but Nanosilver effect was different. Aspergillosis and
Penicillium were eradicated by Nanosilver 80, 100, 150 ppm,
Deconex 2%, Descocid 2% and 4% after 5 minutes contact.
Assessment of disinfectant activity on the environmental
surfaces showed a signiﬁcant difference between the mean
amounts of organisms before and after washing in paired
T-test.
Conclusion: Washing of surfaces at least twice daily can
be suitable to eradicate environmental Staphylococcus,
bacillus and fungi. We must consider recontamination of
hospital surfaces which can occur normally.
OL-053 Quality control of specimens from respiratory
tract using threshold cycle (Ct) values of
ribonuclease P (RNase P) gene for investigation
of the inﬂuenza A (H1N1) by real time PCR
approach
P. Wechagama1,2 *, N. Moonmanee1,2, P. Kriti1,2,
K. Tiangpittayakorn1,2. 1Medical Technology Department,
2Khon Kaen Hospital, Thailand
Background: The novel inﬂuenza A (H1N1) virus is now
rapidly spreading across the world. Early detection is one of
the most effective measures to prevent further transmission
of the virus. However, there is no report regarding the type
of specimens that yield the best result of the Inﬂuenza virus
detection and sufﬁcient amount of cells in the sample.
Methods: The RNase P real time PCR were performed using
four types of specimens, including Nasopharyngeal swab
(NPS), Throat swab (TS), Nasal swab (NS) and Tracheal
aspiration (TA). The RNase P Ct value were then determined
